Merz Pharma Gmbh & Co Kgaa

Merz+co. Gmbh & Co.

Tel Aviv University

Ulthera, Inc.

Merz North America, Inc.

Wojciech Danysz

Ivars Kalvinsh

Valerjans Kauss

Markus Henrich

Christopher Graham Raphael Parsons

Aigars Jirgensons

Markus R Gold

Tanja Weil

Maksims Vanejevs

Jens Nagel

Claudia Jatzke

Christopher Graham Parsons

Aleksandrs Gutcaits

Juris Fotins

Ieva Jaunzeme

Ronalds Zemribo

Andrzej Dekundy

Mirko Hechenberger

Charles D Emery

Hermann Russ

Irene Piskunova

Harry Frank Abts

Patrick Plitt

Peter Kreymerman

Eugene Rozhkov

Angela Bauer

Meik Sladek

Christopher G R Parsons

Jevgenijs Rozhkovs

Igors Starchenkovs

Dina Trifanova

Elina Erdmane

Larisa Kaulina

Sybille Müller

Aleksandra Gutcaits

A method for treating undesired implanted calcium phosphate tissue filler by administering an effective amount of a pharmaceutically acceptable hyperosmotic composition. The hyperosmotic composition may be hyperosmotic solution, particularly a hyperosmotic aqueous solution. The hyperosmotic composition is administration to an area containing the undesired calcium phosphate tissue filler. Administration of the hyperosmotic composition can reduce, dilute/or redistribute an undesired amount or accumulation of implanted calcium phosphate tissue filler implanted. Methods herein can ameliorate undesired filler that is implanted in an undesired or unintended location, that migrates to an undesired location, that results in an undesired visual result, and/or that results in undesired compression of surrounding tissue, and/or that results in pain, infection, and/or inflammation.

Methods and compositions for treating undesired implanted tissue filler

Dermatological cosmetic combination treatments with high intensity focused ultrasound, dermal fillers, fat-reducing compounds, cavitation-prone fluids, and/or septa dissection are provided. A HIFU therapy system can include an imaging system, methods adapted to alter placement and position of a line focus band therapy, multiple simultaneous cosmetic ultrasound treatment zones in tissue, and dithering ultrasound beams from a transducer to alter placement and position of multiple cosmetic treatment zones in tissue. The HIFU systems can include a hand wand, removable transducer modules, and a control module. The dermal fillers can include hydroxyapatite. The fat-reducing compounds can include adipocytolytic compounds, pentacyclic triterpenoid compounds, proapoptotic compounds, compounds impairing differentiation of pre-adipocytes, and combinations thereof. The cavitation-prone fluids can include molecules dissolved in fluids, ethanol, glycerin, and ethylene glycol. The septa dissecting can include using a cutting blade and/or cavitation HIFU. The cosmetic treatment system may be used in various cosmetic procedures, such as treating cellulite.

Systems and methods for combined cosmetic treatment of cellulite with ultrasound

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of &#x3b2;-amyloid (A&#x3b2;) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.

Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Glycine B antagonist

Substituted pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors

The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borne virus, anti-HSV and anti-Hepatitis C virus activity.

[object Object]

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.

1-amino-alkylcyclohexane NMDA receptor antagonists

1-Amino-alkylcyclohexane NMDA receptor antagonists

Pyridyl-phtalazin diones having the following formula: ##STR1## wherein R1 and R2 are selected from the group consisting of hydrogen, halogen, and methoxy or wherein R1 and R2 together form methylenedioxy, and pharmaceutically-acceptable salts thereof, and pharmaceutical compositions containing an effective glycine.sub.B antagonistic amount thereof, are useful in combatting neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission in a living animal, including a human, in need thereof.

Pyrido-phtalazin diones and their use against neurological disorders

Growing community of inventors

Nidderau, Germany

Wojciech Danysz